
    
      Multiple-dose, open-label parallel-group design in patients with mild, moderate or severe
      renal impairment and age (±7 years), sex and weight (±15% BMI) matched healthy subjects.

        -  mild renal impairment: CrCl from 50 to ≤80 ml/min

        -  moderate renal impairment: CrCl from 30 to <50 ml/min

        -  severe renal impairment: CrCl of <30 ml/min
    
  